# US 10,945,989 B2 · Perinatal treatment with a flavonoid agonist of the TrkB receptor for BDNF rescues neurogenesis and behavior in the Ts65Dn mouse model of DS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,945,989 B2
- Document ID: US10945989B2
- Status: Granted
- Kind: B2
- Application number: 16/131,310
- Filed: 2018-09-14
- Published: 2019-03-21
- Granted: 2021-03-16
- Earliest claimed: 2017-09-15
- Assignees: Alma Mater Studiorum - Università di Bologna
- Applicants: ALMA MATER STUDIORUM—Universita' di Bologna
- Inventors: Renata Bartesaghi; Fiorenza Stagni
- Web page: https://patentgrep.com/patent/US10945989B2

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of restoring brain development in individuals with Down syndrome with a flavone derivative, 7,8-dihydroxyflavone (7,8-DHF).

## Claims

### Claim 1

A method of decreasing likelihood of developing intellectual disability in subjects affected by Down syndrome said method comprising:
administering a pharmaceutical composition comprising an effective amount of a TrkB receptor agonist to said subjects and
decreasing the likelihood of said intellectual disability in said subjects, wherein said TrkB receptor agonist is 7,8-dihydroxyflavone.

### Claim 2 (depends on 1)

The method of claim 1, wherein said administering step takes places prenatally.

### Claim 3 (depends on 1)

The method of claim 1, wherein said administering step takes places perinatally.

### Claim 4 (depends on 1)

The method of claim 1, wherein said administering step takes places neonatally.

### Claim 5

A method of treating intellectual disability in subjects affected by Down syndrome said method comprising:
administering a pharmaceutical composition comprising an effective amount of a TrkB receptor agonist to said subjects and
treating said intellectual disability in said subjects, wherein said TrkB receptor agonist is 7,8-dihydroxyflavone.

### Claim 6 (depends on 5)

The method of claim 5, wherein said administering step takes places prenatally.

### Claim 7 (depends on 5)

The method of claim 5, wherein said administering step takes places perinatally.

### Claim 8 (depends on 5)

The method of claim 5, wherein said administering step takes places neonatally.